CTOs on the Move

Invitae

www.invitae.com

 
Invitae is a leader in medical genetic testing, driving genetic information into mainstream medicine to improve healthcare for billions of people. Invitae is aggregating the world`s medical genetic tests into a single service with higher quality, faster turnaround time, and lower prices. By driving down the cost of genetic testing we make it affordable and accessible to everyone who can benefit. Why medical genetics? Within each of us lies information coded in our DNA that can transform our health. Unlocking those answers to make medicine more personalized requires highly specialized, multidisciplinary collaboration. Our platform is setting the standard for the ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.invitae.com
  • 1400, 16th Street
    San Francisco, CA USA 94103
  • Phone: 415.374.7782

Executives

Name Title Contact Details
Danilo Nogueira
Director of Cyber Security and Compliance Profile
Jefferson Webster
Head of Enterprise IT Profile
Karthik Suri
Chief Digital Officer Profile
Dave Ruedger
Chief Information Security Officer Profile

Funding

Invitae raised $1.1B on 04/05/2021

Similar Companies

Human Genome Sciences

Human Genome Sciences, Inc. is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Molecular Designs

Better products. Better service. MOLECULAR DESIGNS Molecular Designs is a team of doctors and scientists working to advance molecular diagnostics. We do this by developing, producing, and supplying multiplex assays for molecular testing ...

Spero Therapeutics

Spero is a multi-asset, clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts dedicated to identifying, developing and commercializing novel treatments focused on unmet needs of patients with multidrug-resistant (MDR) bacterial infections. Spero`s lead product candidate, SPR994, is designed to be the first broad-spectrum oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. Spero also has a platform technology known as its Potentiator Platform that it believes will enable it to develop drugs that will expand the spectrum and potency of existing antibiotics, including formerly inactive antibiotics, against Gram-negative bacteria. Spero`s lead product candidates generated from its Potentiator Platform are two intravenous, or IV,-administered agents, SPR741 and SPR206, designed to treat MDR Gram-negative infections in the hospital setting. Spero is also advancing SPR720, its novel oral therapy product candidate designed for the treatment of pulmonary non-tuberculous mycobacterial infection.

21st Century Medicine Inc

21st Century Medicine Inc is a Rancho Cucamonga, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DMC

DMC is leading the low cost sustainable transformation of multiple product markets.